Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report) and keeping the price target at ...

It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products ...

Ionis Pharmaceuticals posted better-than-expected revenue in the third quarter, but faced challenges as it prepares to bring ...

Following the game-changing success of Spinraza, a molecular-based therapy that was crucial in the treatment of SMA (Spinal Muscular Atrophy), which used to be one of the leading genetic killers of ...

Biogen raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of ...

WELLESLEY, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CLYM) today announced the appointment of Douglas E. Williams, ...

DRI Healthcare Trust (DHTRF) reports a robust 54% increase in cash receipts and expands credit facilities, showcasing strategic growth and investment potential.

The firm expanded its neurology portfolio beyond MS, including the blockbuster Spinraza for spinal muscular atrophy, or SMA, a rare neuromuscular disease. We see Biogen as a firm in transition ...